Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer

Fineline Cube Feb 28, 2026
Company Drug

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis

Fineline Cube Feb 28, 2026
Company R&D

Oxford Study Clears Semaglutide of Neuro/Psychiatric Risks, Suggests Cognitive and Addiction Benefits

Fineline Cube Jul 15, 2024

Researchers at the prestigious Oxford University in the UK have unveiled groundbreaking real-world data on...

Company Drug

Simcere Pharmaceutical’s COVID-19 Therapy Xiannuoxin Earns Full Approval in China

Fineline Cube Jul 12, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that its...

Company Deals R&D

Beijing Tsingke Biotech Partners with Zhejiang University’s Innovation Center for Nucleic Acid Drug Delivery

Fineline Cube Jul 12, 2024

Beijing Tsingke Biotech Co., Ltd., a prominent player in the DNA/RNA synthesis domain based in...

Company Drug

Jiangsu Hengrui’s Subsidiary Conducts First Surgical Dosing in Parkinson’s Gene Therapy Clinical Trial

Fineline Cube Jul 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Medical Device

Medtronic Launches Advanced Signia Stapler in China, Expanding Surgical Capabilities

Fineline Cube Jul 12, 2024

Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced the launch of its intelligent...

Company Drug

Shanghai Escugen Initiates Phase III Clinical Trial for Breast Cancer Drug Candidate ESG401

Fineline Cube Jul 12, 2024

Shanghai Escugen, a biopharmaceutical company based in China, has announced the dosing of the first...

Company Deals

Ipsen Strikes Global Licensing Deal with Foreseen Biotechnology for First-in-Class ADC FS001

Fineline Cube Jul 12, 2024

Ipsen (EPA: IPN; OTCMKTS: IPSEY), a French biopharmaceutical company, has announced a global licensing agreement...

Company Drug

Eisai and Biogen’s Alzheimer’s Therapy Leqembi Receives Marketing Approval in Hong Kong

Fineline Cube Jul 12, 2024

Eisai Co., Ltd, a Japanese pharmaceutical company, along with its co-development partner Biogen Inc. (NASDAQ:...

Company Drug

Pfizer’s Once-Daily Danuglipron Selected for Full Clinical Development for Type 2 Diabetes and Obesity

Fineline Cube Jul 12, 2024

Pfizer Inc. (NSE: PFIZER), a leading pharmaceutical company in the U.S., has announced that a...

Company Drug

Novo Nordisk’s Awiqli Faces FDA Setback as BLA Draws Complete Response Letter

Fineline Cube Jul 12, 2024

Novo Nordisk A/S (NYSE: NVO) announced that the U.S. Food and Drug Administration issued a...

Company Drug

CSPC Pharmaceutical’s RSV mRNA Vaccine SYS6016 Receives Clinical Trial Approval from NMPA

Fineline Cube Jul 12, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Approval for BL-M14D1 Clinical Trial in Solid Tumors

Fineline Cube Jul 12, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

Beijing Sun-Novo Gets NMPA Green Light for STC008 Clinical Trial in Tumor Cachexia

Fineline Cube Jul 12, 2024

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), a biopharmaceutical company based in China, has...

Company Medical Device

Haohai Biotech’s Sodium Hyaluronate Gel Receives NMPA Approval for Aesthetic Treatments

Fineline Cube Jul 12, 2024

Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826, SHA: 688366) has announced that it has...

Company

Danaher Corporation Launches Western Innovation Center in Chongqing

Fineline Cube Jul 12, 2024

Danaher Corporation (NYSE: DHR), a leading science and technology services provider based in the U.S.,...

Company Deals

Salus Biotech Partners with Xi’an Jiaotong University for Single-Cell Omics Innovation

Fineline Cube Jul 12, 2024

Salus Biotech, a Shenzhen-based biotechnology company, has entered into a strategic partnership with the Single-cell...

Company Drug

KeChow Pharma’s Keluping, First NRAS Mutant Melanoma Therapy, Hits the Market

Fineline Cube Jul 12, 2024

Shanghai-based KeChow Pharma has announced the official market launch of its groundbreaking drug, Keluping (tunlametinib),...

Company Deals

Biokin Pharmaceutical Co., Ltd Eyes Secondary Listing on HKEX, Co-Sponsored by Goldman Sachs and Others

Fineline Cube Jul 11, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a company listed on the Shanghai Stock Exchange’s...

Company Deals

Allist Pharmaceuticals Faces Arbitration Over Promotion Agreement for Furmonertinib

Fineline Cube Jul 11, 2024

Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received a...

Company

Bayer Restructures China Business into Five Sectors and Six Departments

Fineline Cube Jul 11, 2024

Bayer (ETR: BAYN), the German pharmaceutical and life sciences giant, has announced a strategic restructuring...

Posts pagination

1 … 293 294 295 … 628

Recent updates

  • Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer
  • Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis
  • Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years
  • Asieris’ APL-1702 MAA Accepted by EMA – First Photodynamic Therapy for Cervical HSIL Nears EU Approval
  • Novartis’ Remibrutinib Wins CHMP Positive Opinion – Oral BTK Inhibitor Nears EU Approval for Chronic Urticaria
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer

Company Drug

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis

Company Drug

Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years

Company Drug

Asieris’ APL-1702 MAA Accepted by EMA – First Photodynamic Therapy for Cervical HSIL Nears EU Approval

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.